Financial News

Nicox announces the presentation of NCX 667 scientific data at AOPT 2017

New preclinical data demonstrate NCX 667’s robust IOP lowering properties Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from…

Read more

Nicox to present at the 6th Annual LEERINK Partners Global Healthcare Conference

Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 6th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 16th, 2017 at 3:00 p.m. Eastern Time. The conference is being held at the Lotte New…

Read more

Nicox provides clinical and regulatory update for NCX 470 for IOP lowering

Positive pre-IND meeting with FDA completed Expect to file IND in Q4 2017 First-in-Human Phase 2 clinical study expected to start in Q1 2018 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide (NO) donating bimatoprost…

Read more
More news